Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569796 | 0.89 | DGAT1 (0.36) | DGAT1MAPT | |
| SCHEMBL15569032 | 0.86 | DGAT1 (0.37) | DGAT1MAPT | |
| SCHEMBL13858243 | 0.83 | DGAT1 (0.40) | DGAT1MAPT | |
| SCHEMBL16968279 | 0.81 | SYK (0.63) | DGAT1 | |
| SCHEMBL28006120 | 0.80 | DGAT1 (0.39) | DGAT1MAPT | |
| SCHEMBL15569591 | 0.79 | SYK (0.56) | DGAT1 | |
| SCHEMBL15569802 | 0.79 | DGAT1 (0.35) | DGAT1MAPTCNR1 | |
| SCHEMBL15570073 | 0.79 | DGAT1 (0.37) | DGAT1MAPT | |
| SCHEMBL23208935 | 0.77 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL15570241 | 0.76 | DGAT1 (0.38) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888262-B1 | PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-12-19 | — | — | EP | disclosed |
| US-9334278-B2 | Pyrrolo[2,3-B]pyrazines as SYK inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334278-B2 | Pyrrolo[2,3-B]pyrazines as SYK inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334278-B2 | Pyrrolo[2,3-B]pyrazines as SYK inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150218170-A1 | PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | US | disclosed |
| US-20150218170-A1 | PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | US | disclosed |
| US-20150218170-A1 | PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | US | disclosed |
| EP-2888262-A1 | PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014029732-A1 | PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218170-A1 | PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS | SYK, ZAP70, BTK | DGAT1 4639/4885MAPT 3356/4885CNR1 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.